Taken together, these results suggest that Sigma1R may offer a plausible mechanism and pharmacological target for improving mood-related symptoms in patients with Dravet syndrome and other DEEs. This evidence concerns the gene SIGMAR1 and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.